NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. and the Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI) have reached an agreement to provide access to Schrödinger’s Materials Science, Biologics, and Small-Molecule Drug Discovery Suites to researchers within Tri-I TDI’s member institutions. The simulation tools are designed to advance early-stage research toward new therapeutics.
“We’re honored to be chosen as a technology platform provider for Tri-I TDI,” said Schrödinger’s president, Dr. Ramy Farid. “We believe our software will complement and contribute meaningfully to their ambitious goal of significantly accelerating drug-discovery projects.”
Tri-I TDI is a unique alliance among Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medical College, and is designed to expedite early-stage drug discovery into novel treatments for patients. Organized as a non-profit corporation that integrates the resources of the three academic partners, its first collaboration is with Takeda Pharmaceutical Company, Ltd, a global research-based pharmaceutical company with extraordinary strengths in medicinal chemistry.
The goal of Tri-I TDI is to assist academic investigators at the three institutions to more rapidly develop therapeutic agents and molecular probes. While Tri-I TDI will focus initially on the development of small molecules, it plans to expand over time to include biologic agents, especially monoclonal antibodies and molecular imaging agents.
“We are very happy to work with Schrödinger, which has a great reputation and is well known for its commitment to scientific breakthroughs,” said Dr. Michael Foley, a celebrated industry veteran and Tri-I TDI’s Sanders Director. “This unprecedented agreement gives the Tri-Institutional community unparalleled access to industry-leading modern drug-discovery and development software tools as well as the training required to employ them to advance our research toward new therapeutics.”
Schrödinger makes significant investments in R&D, which has led to major advances in the field of computational chemistry; it has achieved breakthroughs in quantum chemistry, molecular modeling, force fields, molecular dynamics, protein structure determination, scoring, and virtual screening. The company’s full product offerings range from general molecular modeling programs to a comprehensive suite of drug design software. Besides the company’s industry-leading drug discovery solutions, Schrödinger is actively developing state-of-the art simulation tools for materials research as well as enterprise software that can be deployed throughout an entire research organization. Schrödinger’s methods development and applications papers have thousands of citations and are often among the most-cited scientific publications. Schrödinger’s science is continually validated internally and by its users worldwide. Founded in 1990, Schrödinger has operations in the United States as well as in Europe, India, and Japan. For more information, please visit www.schrodinger.com.
About the Tri-Institutional Therapeutics Discovery Institute
The Tri-Institutional Therapeutics Discovery Institute is a unique partnership among three world-renowned scientific and medical institutions: Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medical College. The Institute works to more effectively develop therapeutics that arise from discoveries made in basic science labs. With a focus on early-stage drug discovery, the Institute provides expertise in medicinal chemistry and compound screening, and conducts “proof of concept” studies needed to demonstrate that drug candidates can successfully alter the course of a disease.
The Institute also works to provide high-quality opportunities for training students and post-doctoral fellows, to deepen faculty involvement in drug discovery, and to support translational research by leveraging the expertise of all three academic institutions and industry partners.
An independent non-profit corporation with its own Board of Directors and Scientific Advisory Board, the Institute will facilitate more efficient sharing of core facilities among the three partner institutions and will form industry partnerships with pharmaceutical and biotech companies to further advance drug research. It will seek to create intellectual property that can be further developed by an open field of industry collaborators.